metaOBS - - Real World Evidence KB

Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament	Trials	Summary Endpoints
Treament	Trials	Demonstrated or suggested benefit	Inconclusive results	Uncertain results	Safety results
IFN alpha	2	demonstrated 28 % increase in clinical improvement suggested 90 % increase in clinical improvement (7-day) suggested 2.9-fold increase in viral clearance suggested 2.5-fold increase in viral clearance by day 7	inconclusive results for: death D28; deaths; clinical deterioration; clinical improvement (14-day); mechanical ventilation; viral clearance by day 14; serious adverse events; adverse events	suggested 4.3-fold increase in clinical improvement (28-day) but the degree if certainty is unassessable demonstrated 76 % increase in clinical improvement (time to event analysis only) but the degree if certainty is unassessable suggested 74 % increase in viral clearance (time to event analysis only) but the degree if certainty is unassessable	-
SNG001 inhaled interferon beta	2	none	inconclusive results for: deaths; clinical deterioration; clinical improvement (time to event analysis only); death or ventilation; hospital discharge; Recovery (time to event analysis only)	suggested 2.3-fold increase in clinical improvement but the degree if certainty is unassessable suggested 3.2-fold increase in clinical improvement (28-day) but the degree if certainty is unassessable suggested 2.2-fold increase in recovery but the degree if certainty is unassessable	-
recombinant super-compound interferon rSIFN-co	1	none	inconclusive results for: deaths; clinical deterioration; clinical improvement (7-day); mechanical ventilation; viral clearance ; viral clearance by day 14; viral clearance by day 7	demonstrated 76 % increase in clinical improvement but the degree if certainty is unassessable suggested 2.9-fold increase in clinical improvement (14-day) but the degree if certainty is unassessable suggested 4.3-fold increase in clinical improvement (28-day) but the degree if certainty is unassessable demonstrated 76 % increase in clinical improvement (time to event analysis only) but the degree if certainty is unassessable suggested 74 % increase in viral clearance (time to event analysis only) but the degree if certainty is unassessable	-